latest news releases from the newsroom
Kos and Jerini Sign Exclusive Collaboration and License Agreement for Development, Marketing and Distribution of Icatibant in The United States and Canada
CRANBURY, N.J. and BERLIN, Nov. 7, 2005 (PRIMEZONE) -- Kos Life Sciences, Inc., a subsidiary of Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) and Jerini U.S. Inc., a subsidiary of Jerini AG (FSE:JI4), announced today the signing of an exclusive agreement for the development, marketing and distribution of Jerini's compound, Icatibant, a potent and specific peptidomimetic bradykinin B2 receptor antagonist, in the United States and Canada. The strategic partnership includes an upfront licensing payment of EUR 12 million (approx. $15 million), along with a EUR 10 million (approx. $12 million) equity investment out of a capital increase at the higher of the weighted average of the closing price of Jerini's shares during the last four trading days, or EUR 3.20 (approx. $3.84) per share (IPO price). Undisclosed milestone payments and sales royalties are also specified in the agreement. Hereditary angioedema (HAE) is the first of several diseases for which Icatibant offers a potential treatment. The agreement outlines collaboration in the HAE area as well as other forms of angioedema, asthma, and refractory ascites in liver cirrhosis (RAIL) indications. Proof-of-concept trials have already been completed in these indications.
MorphoSys and Wacker Demonstrate High Yield Expression of Antibody Fragments
MARTINSRIED, Germany, Nov. 7, 2005 (PRIMEZONE) -- A feasibility study conducted by Wacker Biotech GmbH on behalf of MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) using Fab fragments, demonstrated that Wacker's E. coli secretion system can offer a far simpler and more cost-effective way of obtaining high yields of antibody fragments, which are used for research, diagnostic and therapeutic applications. Under the joint agreement, MorphoSys obtains the right to use Wacker's secretion system for antibody-fragment production in research quantities for therapeutic projects both on its own behalf and with its commercial partners.
SmallCap Sentinel: Sweet November, Historically Hot Market Month Lures Buyers
IRVINE, Calif., Nov. 5, 2005 (PRIMEZONE) -- "A recent USA Today report has highlighted November's historic benevolence to the stock market, denoting that after what is often a cautious October, that 'bullish forces emerge from hibernation and jump-start moneymaking rallies," noted SmallCap Sentinel analyst D.R. Clark. "This could well lead investors into attractive sectors such as biotech where opportunities for potential returns may lay in wait. Investors looking to salvage mediocre years in their portfolios are often more inclined to 'be aggressive' and target possible exponential return equities."
Fidelitas Management, Inc.
Fidelitas Management Changes Name to Archer Entertainment Media Communications Inc.
LOS ANGELES, Nov. 4, 2005 (PRIMEZONE) -- Fidelitas Management, Inc. (Pink Sheets:FDLM) announced that it is formally changing its name to Archer Entertainment Media Communication Incorporated, and in connection with that has applied to the NASD for a new Cusip number and trading symbol to reflect that change. In addition, the Company is proceeding with the filing of its Form 211 to become fully reporting. The company expects to cancel 60, 000,000 common restricted (rule 144) shares. FDLM recently merged with Archer.
Luminetx Corporation Raises $11 Million in Series A Round Financing
MEMPHIS, Tenn., Nov. 4, 2005 (PRIMEZONE) -- Luminetx Corporation, a leading developer and marketer of biomedical technologies, including its patented infrared vein imaging system, VeinViewer(tm), announced today more than $11M in funding has been secured in the company's Series A Preferred financing. Morgan Keegan served as placement agent in the capital-raising effort with Stanford Financial Group as the lead investor. Other investors in the round include Elm Ridge Capital, Capvest Venture Fund, Custer Capital Inc. and its associated funds and Diomed Holdings, Inc.
Delta Air Lines, Inc.
Certain Holders of Delta Air Lines EETCs to Receive Distribution
ATLANTA, Nov. 4, 2005 (PRIMEZONE) -- Delta Air Lines, Inc. today announced that holders of certain series of EETC certificates from its 2001-1, 2001-2 and 2003-1 EETC financings will be receiving a notice from U.S. Bank, the agent for the financings, advising them that a special distribution will be made to certain holders with respect to such certificates. Delta issued equipment notes under the Series 2001-1, Series 2001-2 and Series 2003-1 EETCs to finance a number of aircraft but has not made scheduled payments when due because of its Chapter 11 filing on September 14, 2005. Payments on the notes are used to fund payments on the certificates. Delta will be filing with the bankruptcy court on or before November 14, 2005 election notices under Section 1110(a) of the Bankruptcy Code for the EETC financings. The amount of the special distribution has not yet been determined.
Pacific Advanced Technology, Inc.
GIT to Demonstrate Products for ENI Technology
SANTA BARBARA, Calif., Nov. 4, 2005 (PRIMEZONE) -- Gas Imaging Technology, LLC, (GIT) a manufacturer of unique gas imaging and analysis systems that address critical needs of the oil, gas, utility and chemical industries, announces that the Company has been retained by Energy Laser of Milan to demonstrate its two products, the Sherlock VOC, and an IMSS-based prototype of the Sherlock FE. These products will be used in field trials sponsored by ENI Technology, at a major Italian refinery. GIT is also pleased to announce that the Company was featured on the front page of the Santa Barbara News-Press Business Section on Sunday, October 30, 2005: http://newspress.com/business/103005gasimaging.htm?now=4019&tref=1